Table 3. Table of genotype and phenotype frequency for wild-type, Gli2fl/fl;Gli3fl/+ Wnt1-Cre, Gli2fl/+;Gli3fl/fl;Wnt1-Cre and Gli2fl/fl;Gli3fl/fl;Wnt1-Cre.
| Facial phenotype analyzed [n (%)]‡ | |||||
|---|---|---|---|---|---|
| Genotype | stage | n (%)* | Frontal widening | Bilateral cleft | Duplicated nasal septum |
| Control | e14.5 | 15 (68.18%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Gli2fl/fl;Gli3fl/+;Wnt1-Cre | e14.5 | 2 (9.09%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Gli2fl/+;Gli3fl/fl;Wnt1-Cre | e14.5 | 3 (13.64%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Gli2fl/fl;Gli3fl/fl;Wnt1-Cre | e14.5 | 2 (9.09%) | 2 (100%) | 2(100%) | 2 (100%) |
| Control | e15.5 | 21 (63.64%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Gli2fl/fl;Gli3fl/+;Wnt1-Cre | e15.5 | 3 (9.09%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Gli2fl/+;Gli3fl/fl;Wnt1-Cre | e15.5 | 5 (15.15%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Gli2fl/fl;Gli3fl/fl;Wnt1-Cre | e15.5 | 4 (12.12%) | 4 (100%) | 4(100%) | 4 (100%) |
Genotypes of control including Gli2fl/fl;Gli3fl/+, Gli2fl/+;Gli3fl/fl, Gli2fl/+;Gli3fl/+, Gli2fl/+;Gli3fl/+;Wnt1Cre.
*n, number of embryos analyzed; %, percentage relative to the number of total embryos (total embryos for e14.5 n = 22; for e15.5 n = 33).
‡n, number of embryos presenting phenotypes; %, percentage relative to the number of embryos analyzed.
Frontal widening is defined by a distance between nasal pits greater than 1.8 mm in e14.5 and e15.5 embryos.
Bilateral clefting is defined by a patent area greater than 0.253mm2 in e14.5 and e15.5 embryos